https://www.prnewswire.com/news-releases/fda-approves-pembrolizumab-for-pancreatic-cancers-with-mismatch-repair-deficiency-300462874.html
/PRNewswire-USNewswire/ -- In an unprecedented, fast-tracked review, the Food and Drug Administration (FDA) approved the use of pembrolizumab (anti-PDI)...
mismatch repair deficiencypancreatic cancersfdapembrolizumab